Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058045 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00058045 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 1 participants.
The verdict
NCT00058045, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of cancer therapy. PURPOSE: Phase I trial to study the effectiveness of combining interleukin-2 with stem cell factor in treating patients who have AIDS or AIDS-related cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant human stem cell factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058045
The ClinicalTrials.gov registry entry for NCT00058045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aldesleukin is the first listed.
NCT00058045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058045 about?
NCT00058045 is a clinical study titled "Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of cancer therapy. PURPOSE: Phase I trial t...
What is the current status of trial NCT00058045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2002-08.
What interventions are being tested in trial NCT00058045?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant human stem cell factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00058045?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.